HCW Biologics Inc is trading 5.5% down at $1.03 as it extends a week-long pullback following a sharp speculative rally earlier in June.
- The pre-market dip appears to be a normal fluctuation driven by the stock's high historical volatility, as there are no fresh company-specific headlines or analyst actions this morning to explain the move.
- Recent news for the company has been positive, including a June 16 announcement of preliminary Phase 1 data for its fusion immunotherapeutic HCW9302 in treating alopecia areata.